Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme

References

• Vivianco I, Sawyers CL. The phosphophatidylinositol 3-kinase/AKT pathway in human cancer. Nat. Rev. Cancer2, 489–501 (2002).
   PubMedGoogle Scholar
• Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol.4, 648–657 (2002).
   PubMed Web of Science ®Google Scholar
• Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell10, 151–162 (2002).
   PubMed Web of Science ®Google Scholar
• Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol.4, 658–665 (2002).
   PubMed Web of Science ®Google Scholar
• Garami A, Zwartkruis FJ, Nobukuni T et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC 1 and 2. Mol. Cell11, 1457–1466 (2003).
   PubMed Web of Science ®Google Scholar
• Saucedo LJ, Goa X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/mTOR signaling network. Nat. Cell Biol.5, 566–571 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. Nat. Cell Biol.5, 578–581 (2003).
   PubMed Web of Science ®Google Scholar
• Im E, von Lintig FC, Chen J et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene21, 6356–6365 (2002).
   PubMed Web of Science ®Google Scholar
• Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb promotes tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem.278, 32493–32496 (2003).
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson AR, Tee L, Cheatham C, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol.24, 200–216 (2004).
   PubMed Web of Science ®Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene23, 3151–3171 (2004).
   PubMed Web of Science ®Google Scholar
• Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4E-BP1/eIF4E. Genes Dev.16, 1472–1478 (2002).
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation inhibition by FRAP/mTOR. Genes Dev.15, 807–826 (2001).
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediated TOR action. Cell110, 177–189 (2002).
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell110, 163–175 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham RT. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell111, 9–12 (2002).
   PubMed Web of Science ®Google Scholar
• Radimerski T, Montagne J, Rintleen F et al. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat. Cell Biol.4, 251–255 (2002).
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signaling. Biochem. Soc. Trans.31, 573–578 (2003).
   PubMed Web of Science ®Google Scholar
• Stolovich M, Tang E, Hornstein G et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phophatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell Biol.22, 8101–8113 (2002).
   PubMedGoogle Scholar
• Janus A, Robak T, Smolewski P. The mammalian target of rapamycin (mTOR) kinase pathway: Its role in tumourgenesis and targeted antitumor therapy. Cell Mol. Biol. Lett.10, 479–498 (2005).
   PubMed Web of Science ®Google Scholar
• Jin W, Wu L, Llang K, Llu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br. J. Cancer89, 185–191 (2003).
   PubMed Web of Science ®Google Scholar
• Gottschalk AR, Basila D, Wong M et al. p27 Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res.61, 2105–2111 (2001).
   PubMed Web of Science ®Google Scholar
• Schlieman MG, Gahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer89, 2110–2115 (2003).
   PubMed Web of Science ®Google Scholar
• Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell4, 147–184 (2003).
   PubMed Web of Science ®Google Scholar
• De Benedetti A, Graff JR. eIF4E expression and its role in malignancies and metastases. Oncogene23, 3189–3199 (2004).
   PubMed Web of Science ®Google Scholar
• Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer8, 237–248 (2001).
   PubMed Web of Science ®Google Scholar
• Ward SG. Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol.3, 426–434 (2003).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin.55, 178–194 (2005).
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther.2, 169–177 (2003).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol.16, 564–575 (2004).
   PubMed Web of Science ®Google Scholar
• Law M, Forrester E, Chytil A et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res.66, 1070–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol.4, 75–85 (2003).
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer3, 721–732 (2003).
   PubMed Web of Science ®Google Scholar
• Blagoskonny MV, Darzynkiewicz Z. Four birds with one stone: RAPA as potential anticancer therapy. Cancer Biol. Ther.1, 359–361 (2002).
   PubMedGoogle Scholar
• Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin.55, 178–194 (2005).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer JI et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol.23, 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Forouzesh B, Buckner JC, Marks AJ et al. Phase 1, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies: 2002 EORTC-NCI-AACR Symposium on Molecular targets and Cancer Therapeutics. Eur. J. Cancer54, 168 (2002).
   Google Scholar
• O’Reilly T, Vaxelaire J, Muller M et al. In vivo activity of RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc. Am. Assoc. Cancer Res. (2002) (Abstract 359).
   Google Scholar
• Clackson T, Metcalf III CA, Rozamus LW et al. Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc. Am. Assoc. Cancer Res.43, 95 (2002) (Abstract LB).
   Google Scholar
• Pacey S, Rea D, Steven N, Brock C et al. Results of Phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, Rad001) and Gemcitabine (GEM) in patients (pts) with advanced cancers: 2004 ASCO Meeting. J. Clin Oncol.22, 3120 (2004).
   PubMedGoogle Scholar
• Dudkin L, Dilling MB, Cheshire PJ et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res.7, 1758–1764 (2001).
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kerr K, Tang CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res.61, 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin. Ann. Oncol.16, 525–537 (2005).
   PubMed Web of Science ®Google Scholar
• Rivera V, Tang H, Metcalf C et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc. Am. Assoc. Cancer Res.45, 3887 (2004).
   Google Scholar
• LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differentiation10, 66–75 (2003).
   PubMed Web of Science ®Google Scholar
• Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev.14, 337–348 (2003).
   PubMed Web of Science ®Google Scholar
• Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Path. Oncol. Res.7, 95–106 (2001).
   PubMedGoogle Scholar
• Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand induces death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem.277, 25020–25025 (2001).
   Google Scholar
• Nam SY, Jung GA, Hur GC et al. Upregulation of FLIPs by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci.94, 1066–1073 (2003).
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Maecker H, Sharp D et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis-factor related apoptosis-inducing ligand. J. Biol. Chem.280, 40599–40608 (2005).
   PubMed Web of Science ®Google Scholar
• Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev.16, 33–45 (2001).
   Google Scholar
• Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL – or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med.8, 807–815 (2002).
   Google Scholar
• Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol.25, 8809–8823 (2005).
   PubMed Web of Science ®Google Scholar
• Karin M, Lin A. NF-κB at the crossroads of life and death. Nat. Immunol.3, 221–227 (2002).
   PubMed Web of Science ®Google Scholar
• Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem.276, 37879–37866 (2001).
   PubMed Web of Science ®Google Scholar
• Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide K, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res.62, 7291–7297 (2002).
   PubMed Web of Science ®Google Scholar
• Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer5, 876–885 (2005).
   PubMed Web of Science ®Google Scholar
• Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res.10, 7031–7042 (2004).
   PubMed Web of Science ®Google Scholar